# TERN-701

Type: Product

Source: Startup Intelligence Brief — https://getstartupbrief.com/entity/tern-701-product
Canonical HTML page: https://getstartupbrief.com/entity/tern-701-product

## Recent coverage (1 stories)

### Merck Strikes $6.7B Terns Acquisition to Counter Keytruda Patent Cliff
2026-03-25 19:20:53 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Full story: https://getstartupbrief.com/story/merck-acquires-terns-pharmaceuticals-6-7b

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getstartupbrief.com/guides/methodology for the full editorial methodology.